secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2022-07-20T23:59:59+00:00
Accession:  0001104659-22-081006
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q2 EPS $1.14 GAAP, $1.43 adj; raises FY adj EPS view to $4.90+
---------------------------------------------------------------------

- Q2 sales $11.3B (+10.1% reported, +14.3% organic); GAAP EPS $1.14, adjusted EPS $1.43 (+22.2%).
- COVID-19 testing sales $2.3B in Q2; full-year COVID testing revenue projected at $6.1B.
- Raised FY 2022 GAAP EPS guidance to at least $3.50, adjusted EPS to at least $4.90.
- Nutrition sales down 7.4% reported due to infant formula recall; Adult Nutrition organic growth +5.2%.
- Medical Devices organic growth +7.5% driven by Diabetes Care FreeStyle Libre (+25.6% organic).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000110465922081006/0001104659-22-081006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000110465922081006/tm2221376d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-081006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer